Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genesis Healthcare Inc GENN

Healthcare Medical Care
Genesis Healthcare, Inc. is a holding company. The Company provides services to skilled nursing facilities and assisted/senior living communities. It also specializes in contract rehabilitation therapy, respiratory therapy, physician services, staffing services, and accountable care. It provides approximately 250 skilled nursing centers and senior living communities in 22 states nationwide. Its... see more

Recent & Breaking News (GREY:GENN)

Major Shareholder Announcement

GlobeNewswire August 25, 2014

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance

GlobeNewswire August 13, 2014

Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma

GlobeNewswire August 11, 2014

GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire July 31, 2014

Second Quarter 2014 Net Sales Figures for Arzerra(r)

GlobeNewswire July 23, 2014

Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma

GlobeNewswire July 18, 2014

Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire July 7, 2014

GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy

GlobeNewswire July 3, 2014

GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL

GlobeNewswire June 27, 2014

Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology Company

GlobeNewswire June 4, 2014

Genmab Announces Ofatumumab Development Plans in RRMS and NMO

GlobeNewswire May 30, 2014

GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy

GlobeNewswire May 23, 2014

GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

GlobeNewswire May 19, 2014

Genmab Announces Financial Results for the First Quarter of 2014

GlobeNewswire May 7, 2014

Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance

GlobeNewswire May 1, 2014

First Quarter 2014 Net Sales Figures for Arzerra

GlobeNewswire April 30, 2014

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate

PR Newswire April 17, 2014

GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate

GlobeNewswire April 17, 2014

Passing of Genmab A/S' Annual General Meeting

GlobeNewswire April 9, 2014

Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire March 26, 2014